KPV
Anti-Inflammatory Tripeptide | Alpha-MSH Fragment
KPV is a potent anti-inflammatory tripeptide derived from the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). This small but powerful peptide exhibits remarkable anti-inflammatory and antimicrobial properties without the pigmentation effects of full α-MSH. KPV has shown particular promise for inflammatory bowel diseases, skin conditions, and immune modulation through its ability to penetrate cells and interact directly with inflammatory signaling pathways.
Daily dose
200-500mcg
Frequency
1-2 times daily
Cycle length
4-8 weeks
Storage
2-8°C (refrigerated)
Key benefits
Systemic anti-inflammatory effects, immune modulation, potential for autoimmune conditions
How it works
Enters cells and inhibits inflammatory pathways at the nuclear level, particularly NF-κB signaling
Dosage protocols
Goal
General Anti-Inflammatory
Dose
200-300mcg · Once daily
Route
Subcutaneous
Goal
Active Inflammation
Dose
250mcg · Twice daily
Route
Subcutaneous
Goal
Autoimmune Support
Dose
500mcg · Once daily
Route
Subcutaneous
Goal
Acute Flare-ups
Dose
500mcg · Twice daily for 1 week then reduce
Route
Subcutaneous
Research indications
inflammation
gut Health
immune Function
Administration
Interactions
Safety notes
Excellent safety profile with minimal side effects
Does not cause immunosuppression like steroids
No melanin production or tanning effects
May temporarily reduce inflammation-related symptoms
Monitor for signs of infection (rare)
Generally well-tolerated even at higher doses
Research studies
Antimicrobial Properties Against Gut Pathogens (2022)
In vitro | Multiple bacterial strains | MIC determination
KPV showed selective antimicrobial activity against pathogenic bacteria while preserving beneficial gut microbiota, suggesting prebiotic-like properties.
KPV for Psoriasis and Dermatitis (2021)
Human cells + Animal model | Topical application | 4 weeks
Topical KPV reduced psoriatic markers by 60% and improved skin barrier function, showing promise as a steroid-sparing treatment option.
Anti-Inflammatory Mechanisms of KPV (2020)
In vitro | Various concentrations | Cell culture studies
Revealed KPV enters cells and directly inhibits NF-κB pathway, reducing TNF-α, IL-6, and other inflammatory cytokines at the transcriptional level.
KPV in Inflammatory Bowel Disease Models (2019)
Animal model | Oral and injection | 14 days | Colitis model
Demonstrated significant reduction in inflammatory markers and improved intestinal barrier function in IBD models, with both oral and injectable forms showing efficacy.